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Purpose: The cost-effectiveness of ﬁrst-line chronic
lymphocytic leukemia treatments was assessed among
patients unsuitable for full doses of ﬂudarabine.
Methods: The study’s key outcome was the life-
time incremental cost-effectiveness ratio (ICER)
(euro/quality-adjusted life-year [QALY] gained) with
an annual 3% discounting. A probabilistic Markov
model with 3 health states (progression-free, progres-
sion, and death) was developed. Survival time was
modeled based on age-matched clinical data by using
appropriate survival distributions. Each health state
was assigned an EuroQoL-5D-3L quality-of-life
estimate and Finnish payer costs according to treat-
ment received, and Binet stage of disease; severe
adverse events and treatment inconvenience were also
included. Six approaches considered the risk and value
of key outcomes: cost-effectiveness efﬁciency frontiers;
Bayesian treatment ranking (BTR) rated the lowest
ICERs and best QALY gains; the cost-effectiveness
acceptability frontier demonstrated optimal treatment;
expected value of perfect information; and the cost–
beneﬁt assessment (CBA), a type of clinical value
analysis, increased the clinical interpretation and
appeal of modeled outcomes by including both rela-
tive and absolute (impact investment [beneﬁt obtained
with a ﬁxed limited budget]) beneﬁt assessments.
Findings: The ICERs compared with chlorambucil
varied from €29,334 with obinutuzumab þ chlorambu-
cil to €82,159 with ofatumumab þ chlorambucil. Based*Mrs. Hautala is currently an employee of Farenta Oy, Espoo,
Finland.
**Dr. Kyttälä is currently an employee of Roche Pharma AG,
Grenzach-Wyhlen, Germany.
April 2016on the BTR of ICERs versus chlorambucil, obinutuzu-
mab þ chlorambucil was the most cost-effective with
93% probability; rituximab þ chlorambucil was the
second most cost-effective (73%); and rituximab þ
bendamustine was the third most cost-effective (65%).
The ICERs of obinutuzumab þ chlorambucil were
€20,038, €11,556, and €15,586 compared with ritux-
imab þ chlorambucil, rituximab þ bendamustine, and
ofatumumab þ chlorambucil. Obinutuzumab þ chlor-
ambucil was the most cost-effective treatment, with
54% and 99% probability at €30,000 and €50,000/
QALY gained, respectively. The corresponding expected
values of perfect information were €1438 and €44 per
patient. Based on the BTR of QALYs gained, obinutu-
zumab þ chlorambucil was the most effective, with
100% probability; rituximab þ chlorambucil was the
second most effective (56%); and rituximab þ bend-
amustine was the third most effective treatment (81%).
Results were robust in sensitivity analyses. For obinutu-
zumab þ chlorambucil, the CBA demonstrated the best
clinical value–to–cost-effectiveness relation and the lon-
gest time progression-free with a limited budget.
Implications: The mean results were sensitive to
large changes in time horizon, indirect comparison
hazard ratios, survival distributions, and discounting;
however, obinutuzumab þ chlorambucil provided con-
siderable effectiveness and best value for money among
chronic lymphocytic leukemia patients unsuitable toAccepted for publication February 3, 2016.
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Clinical Therapeuticsreceive full doses of ﬂudarabine. In this case, CBA
concurred with the key outcome of the study. How-
ever, the CBA cannot fully substitute the key outcome,
and further cost-effectiveness studies with different
cancer types are needed to assess the validity of a
limited CBA. (Clin Ther. 2016;38:889–904) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
Key words: bendamustine, chronic lymphocytic
leukemia, economic evaluation, obinutuzumab, ofatu-
mumab, rituximab.INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most
common type of leukemia, accounting for 25% to
40% of all leukemias.1,2 The annual incidence of CLL
is 2 to 6 per 100,000 population,1,3 with a prepon-
derance of male subjects over female subjects. CLL is
more common in elderly people, with almost one half
of the newly diagnosed CLL patients being at least 75
years of age. CLL causes signiﬁcant humanistic4–10
and economic9,11,12 burdens.
Immunochemotherapy with rituximab þ ﬂudara-
bine þ cyclophosphamide (RFC) has been the stand-
ard ﬁrst-line treatment for patients with CLL who
require and can tolerate intense chemotherapy. How-
ever, older patients with comorbidities are often
ineligible for RFC.13 For these patients, chlorambucil
monotherapy (Clb) is often used, even though it rarely
induces complete responses.14–16 Currently, combinationProgression
survival with
active treatm
Progression-free
   survival with
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Progression
Figure 1. Simplified presentation of the Markov model.
890regimens, including obinutuzumab þ chlorambucil
(GClb), ofatumumab þ chlorambucil (OClb), ritux-
imab þ bendamustine (RB), and rituximab þ chlor-
ambucil (RClb), are considered because of their
efﬁcacy and limited toxicity.
The present study is the ﬁrst to estimate the cost-
effectiveness of all relevant treatments among patients
with CLL unsuitable for full-dose ﬂudarabine and, thus,
RFC therapy to the best of our knowledge. It is also
probably the ﬁrst to elaborate on the results of a full
health economic assessment involving 6 different meth-
ods: cost-effectiveness efﬁciency frontiers; Bayesian
treatment ranking (BTR); cost-effectiveness acceptability
frontier (CEAF); expected value of perfect information
per patient (EVPI); limited cost–beneﬁt assessment
(CBA), which is a clinical value analysis; and impact
investment analysis (IIA) based on the CBA.MATERIALS AND METHODS
A decision-analytic modeling approach was used to
conduct the cost-effectiveness analysis (CEA) pre-
sented here. This CEA meets the Finnish requirements
for health economic evaluations,17 which concurs
with most European guidelines.18–27
Clb, GClb, OClb, RB, and RClb were compared by
using a probabilistic, long-term, Markov transition
model (Figure 1) with 3 mutually exclusive key health
states in patients with CLL who were unsuitable for
RFC. A 1-week model cycle length with life-table
method of half-cycle correction28,29 was applied.Death
-free
out
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This CEA included a cohort of adult CLL patients
with comorbidities or physical decline. The cohort’s
characteristics were based on Finnish-speciﬁc features
and the CLL11 trial15 assessing Clb, GClb, and RClb in
previously untreated patients with CLL. Fifty percent of
the Finnish cohort members were male (60% in CLL11).
The proportion of cohort members with Binet stages A,
B, and C were 22%, 42%, and 36%, respectively, in
CLL11. The mean age, weight, and height were 71.7
years, 73.7 kg, and 166.7 cm in CLL11. The mean
estimated body surface area was 1.8 m2.30Progression-free Survival
The CEA was based on individual patient data from
CLL11 (An Open-label, Multi-center, Three Arm
Randomized Study to Investigate the Safety and Efﬁcacy
on Progression-free Survival of RO5072759 þ Chloram-
bucil (GClb) Compared to Rituximab þ Chlorambucil
(RClb) or Chlorambucil (Clb) Alone in Previously Un-
treated CLL Patients With Comorbidities), including
progression-free survival (PFS) for Clb, GClb, and RClb
(March 3, 2014 data cut16), and aggregated PFS from
Knauf et al,14,31 COMPLEMENT 1 (Ofatumumab þ
Chlorambucil vs Chlorambucil Monotherapy in Previ-
ously Untreated Patients With Chronic Lymphocytic
Leukemia)32 for OClb, and CLL10 (Phase III Trial of
Combined Immunochemotherapy With Fludarabine,
Cyclophosphamide and Rituximab (FCR) Versus
Bendamustine and Rituximab (BR) in Patients With Pre-
viously Untreated Chronic Lymphocytic Leukaemia)33
for RB. The CLL11 trial program had 2 stages for
GClb and RClb, with stage 1 being a subgroup of stage
2. The stage 2 individual patient data from CLL11 were
used for GClb and RClb. For Clb, only the stage 1
individual patient data were available. The baseline
characteristics of patients in the key trials are reported
in Supplemental Table I (as shown in the online version
at http://dx.doi.org/10.1016/j.clinthera.2016.02.005). The
key differences were as follows: the CLL11 patients were
older, had more comorbidities, and had worse creatin-
ine clearance compared with the COMPLEMENT 1
or CLL10 patients. Unlike the CLL11 and
COMPLEMENT 1 patients, the CLL10 patients
had a low Cumulative Illness Rating Scale, and the
patients were basically suitable for ﬂudarabine
treatment. The dosing regimens of the trials are
reported in the Costs section of this article.April 2016All simulated cohort members started the model in
the PFS health state, on treatment, and could progress,
die, or discontinue treatment based on the actual
treatment duration in line with the CLL11 results.
Because the maximum treatment duration was 6
cycles in CLL11, parametric survival functions were
not used for treatment duration, but the actual
proportions of patients on treatment from CLL11
were used.
Weibull’s parametric survival distribution was se-
lected to model the CLL11 PFS based on statistical
tests, the Akaike information criterion, visualization,
and expected PFS times from longer term clinical
studies. The following parameter values (SEs) were
used: Clb intercept, 2.591 (0.065); Clb scale, 0.636
(0.049); GClb intercept 3.628 (0.057); GClb scale,
0.635 (0.046); RClb intercept, 3.070 (0.036); and
RClb scale, 0.560 (0.029). Cholesky decomposition
was applied to include the correlation of survival
model parameters.34
For the comparison versus OClb and RB, a Baye-
sian meta-analysis35 with age adjustment was
available. The hazard ratios (HRs) were converted
into logarithmic HRs to inform probabilistic
sensitivity analysis distributions, and they were used
to adjust the PFS estimates of RB and OClb: GClb
versus RB, HR of 0.412 (lnHR, –0.937; SD, 0.314);
GClb versus OClb, HR of 0.295 (lnHR, –1.241; SD,
0.203).
The probability of death during PFS was the
maximum of death rate in CLL11 and the Finnish
age- and gender-speciﬁc mortality in 2013.36,37 Sur-
vival curves are depicted in Figure 2.
Postprogression Survival
After progression, the proportion of cohort mem-
bers with Binet stages A, B, and C were 14.5%,
47.2%, and 37.8%, respectively.38 Postprogression
survival (PPS), the transition from progressive disease
to death, was modeled based on the CLL5
(Fludarabine Versus Chlorambucil in First Line
Therapy of Elderly Patients (More Than 65 Years)
With Advanced Chronic Lymphocytic Leukemia) trial
(January 14, 2013, data-cut) due to immaturity of
overall survival and crossover in CLL11. Applicability
was ascertained by taking into account the age of
patients at the time of disease progression by using an
exponential parametric survival model with age as a
covariate (SE): intercept, 6.492 (1.920); age, –0.035891
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Figure 2. (A) Ten-year progression-free survival (PFS) and (B) 20-year overall survival (OS) related to
treatments. Clb ¼ chlorambucil alone; GClb ¼ obinutuzumab þ chlorambucil; KM ¼ observed
Kaplan-Meier; OClb ¼ ofatumumab þ chlorambucil; RB ¼ rituximab þ bendamustine;
RClb ¼ rituximab þ chlorambucil.
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E. Soini et al.(0.027). The exponential model was selected based on
the Akaike information criterion, visual inspection,
and expected overall survival from longer term clinical
studies and Finnish data.39 Cholesky decomposition34
was applied for PPS.
Costs
Direct health state–speciﬁc costs were applied based
on the treatments and Binet stages (Table I). Costs
consisted of drug acquisition, drug administration,
monitoring, follow-up, progression/relapse resources,
postprogression treatment, and treatment of serious
adverse events (SAEs). Indirect costs and losses such as
absenteeism, presenteeism, caregiver and time costs,
and disutilities due to informal care were ignored
according to the Finnish guidance17 and CLL11 mean
patient age exceeding the Finnish retirement age.
Drugs
The actual treatment duration and dosing from the
trials were used without vial sharing. Furthermore, a
distinction was made between the ﬁrst and consecutive
drug administrations and is shown in Table I, which
also reports the dosing regimens from the trials. The ﬁrst
dose of obinutuzumab may be given on 1 day or split
over 2 consecutive days. Not beneﬁting obinutuzumab
in terms of administration costs, 1 vial split to 100 mg
day 1 and 900 mg day 2, and consequent higher drug
administration cost was assumed (ie the 1000 mg vial
may be given in day 1 and lower drug administration
may be used). Up-to-date costs [40,41] were used
together with the cost correction for administration
time needed in order not to underestimate the admini-
stration cost of intravenous drugs (see [42]).
Individual patient drug utilization data were avail-
able for Clb, GClb, and RClb. For OClb, the esti-
mated treatment duration was, on average, 6.4 cycles
of a planned 12 cycles (ie, 53.3%)32 with 100%
assumed dose intensity. For RB, the mean number of
treatment cycles was 5.41 of a planned 6.00.33 The
mean dose was estimated to be 96.84% (ie, 90.0% *
31.6% þ 100% * 68.4% based on Eichhorst et al33).
Postprogression cancer drugs were based on CLL5
(6.5 months of Clb 0.5 mg/kg38 together with
administration/monitoring costs).
Adverse Events
Grade 3 to 5 SAEs observed in CLL11 individual
patient data, COMPLEMENT 1,32 and CLL1033 wereApril 2016included based on their potential association with
CLL treatment. For OClb and RB, a maximum 1
SAE/preferred term was included,32,33 whereas for
Clb, GClb, and RClb, multiple SAEs/preferred term
or patient was possible. This inconsistency resulting
from the publications beneﬁted OClb and RB com-
pared with Clb, GClb, or RClb. All expected SAE
costs (Supplemental Table II [as shown in the online
version at http://dx.doi.org/10.1016/j.clinthera.2016.
02.005]) were applied in the ﬁrst model cycle.
A sensitivity analysis (Supplemental Appendix I [as
shown in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.02.005]) incorporated AEs
based on the CLL11 publication.15
Binet and End-stage
The resources were partitioned based on Binet
stages. Based on the Finnish experience, the following
annual resources were ﬁxed for all: 1 primary care
visit (€116.18), 1 specialist visit (€309.04), and a
comprehensive blood test.40,41 In addition, the follow-
ing factors were considered annually: Binet stage A,
2.67 primary care calls (€27.46/call) and 4.80 calls if
progressed; Binet stage B, 3.00 primary care calls
(4.80 calls and 1 specialist visit if progressed); and
Binet stage C, 4.80 primary care calls and 1 specialist
visit. One blood cell count þ neutrophil assessment
per visit were included.
Based on the Finnish experience, end-stage treatment
consisted of pneumonia in 40% of patients (€7827.49
per hospitalization40,41); autoimmune hemolytic ane-
mia or immune thrombocytopenia in 5% of patients13
(10-day hospital stay for autoimmune hemolytic
anemia/immune thrombocytopenia, €6205.0640,41);
and 1 primary care call per week for the last 2 months
(included as an expected cost during the PPS).
Quality-adjusted Survival
Patient utility was based on a recent UK utility
elicitation study with validated health states and
EuroQoL-5D-3L (EQ-5D-3L) dimensions.10 The
impact of on/off treatment on quality of life (QoL)
was accounted for. The UK utility values based on
elicitation were adjusted to take into account the
representative EQ-5D-3L tool-based generic QoL of
65- to 74-year-old Finns together with their symp-
toms/comorbidities (adjusting factor 0.776/0.820
based on the EQ-5D-3L QoL of 65- to 74-year-old
Finns per utility with PFS off- treatment [43]/[10],893
Table I. Treatment-related resources and costs.
Treatment Drug, mg
Drug (€)/Cycle
Administration Time
Administration
€/Cycle Other Medications/Cycle
1st 2nd 1st† 2nd† 1st 1st, € 2nd 2nd, €
Clb* po (0.5/kg  2) 119.59 119.59 Not needed 0 0 Not needed
GClb* 11,614.96 3951.38 1530.17 364.17 Day 1,
Day 2:
Drugs 1
66.61 Drugs 2 0.39
Obinutuzumab IV (cycle 1, 3000
for 4 d; later, 1000 for 1 day)
11,495.37 3831.79 Cycle 1, 4 h, 4 days 1530.17 364.17
Later, 3.25 h
Chlorambucil po (0.5/kg  2) 119.59 119.59 Not needed 0 0
OClb* 3018.68 2372.90 826.34 382.54 Drugs 1 33.31 Drugs 1 33.31
Ofatumumab IV (cycle 1, 1300
for 2 d; later, 1000 for 1 d)
2798.38 2152.60 Cycle 1, 6 h Day 1, 4.5 h
Day 8 Later, 4 h
826.34 382.54
Chlorambucil po (10/m2  7) 220.30 220.30 Not needed 0 0
RB* 3199.66 4077.18 1098.63 654.84 Drugs 3 0.48 Drugs 3 0.48
Rituximab IV (cycle 1, 375/m2
for 2 d; later, 500/m2 for 1 d)
2047.54 2925.05 Cycle 1, 4 h Day 1, 4 h
Day 2 Later, 1.5 h
765.09 321.29
Bendamustine IV (90/m2  2, 2
d/cycle)
1152.13 1152.13 Cycle 1: þ1 h Day 2, 1 h
Day 3
333.54 333.54
Later: þ1 h Day 1, 1 h
Day 2
RClb* 2167.13 3044.64 765.09 321.29 Drugs 2 0.39 Drugs 2 0.39
Rituximab IV (cycle 1, 375/m2
for 2 d; later, 500/m2 for 1 d)
2047.54 2925.05 Cycle 1, 4h Day 1, 4h
Day 2. Later, 1.5h
765.09 321.29
Chlorambucil po (0.5/kg  2) 119.59 119.59 Not needed 0 0
Clb ¼ chlorambucil alone; GClb ¼ obinutuzumab þ chlorambucil; OClb ¼ ofatumumab þ chlorambucil; RB ¼ rituximab þ bendamustine; RClb ¼ rituximab þ
chlorambucil; po ¼ orally;
*In addition, cycle 1 monitoring included the following: 1 specialist visit (€309.04/visit40; index, 1.05619841); 3 blood cell counts þ neutrophils; 1 creatinine
measurement; and assessment of alanine transaminase, alkaline phosphatase, C-reactive protein, potassium, sodium, urate, and l-day enzyme levels (tests total
€18.69/cycle); that is, total of €327.73/ﬁrst cycle. Later monitoring/cycle included the following: 0.25 specialist clinician visit; 0.75 specialist clinician call (€27.46/
call40,41); and 3 blood cell count þ neutrophils (tests total €7.60/cycle); that is, a total of €105.46/cycle when on treatment.
†To avoid the underestimation of the intravenous drug administration costs,42 the administration cost was approximated by using specialist health care visit/
administration (1 hour of time included) and additional time counted with nurse’s employment cost (€24.50/hour40,41). Drugs 1 included corticosteroid prednisolon
100 mg IV, the antihistamine cetirizine 10 mg, and paracetamol PanadolR 1 g po. Drugs 2 included cetirizine 10 mg and paracetamol 1 g po. Drugs 3 included
cetirizine 10 mg, paracetamol 1 g, and antiemetic metoclopramide 10 mg po. Drug costs were taken from the Finnish Medicines Tariff 9/2014.
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E. Soini et al.which was used as an adjusting multiplier for the
utility values based on the elicitation10). Expected PPS
and the adjusting factor were taken into account in the
postprogression QoL estimate.
The mean (SD) QoL values were as follows: 0.672
(0.189) PFS with nonintravenous treatment, 0.634
(0.208) PFS with intravenous treatment, 0.520 (0.246)
PFS with increased hospital visits, 0.776 (0.181) PFS off-
treatment (mean equivalent to the EQ-5D-3L QoL of 65-
to 74-year-old Finns43), and 0.563 for PPS. Treatment
inconvenience was assumed to last the longest between
2 planned treatment administrations (eg, GClb 4 weeks).
The disutility due to increased hospital visits affected
only GClb, although administration of RB and RClb can
also be associated with multiple visits.
Time Horizon
Health outcomes should be modeled over the
remaining lifetime of the patients34 if a mortality
difference is expected. With the base-case settings,
1.7% of the GClb cohort was predicted to be alive
within 20 years, and thus a 20-year time horizon
was used. Adhering to the Finnish guidelines,17 all
outcomes were discounted with 3% per year.
Distributions
The second-order Monte Carlo simulation with
2000 simulations was conducted by using Visual Basic
for Applications for Microsoft Excel 2013 (Microsoft
Corporation, Redmond, Washington) and was used to
jointly take into account variation in the outcomes
due to potential sampling uncertainty related to the
model parameters. β-Distributions were used for QoL
values, multivariate normal distributions for para-
metric PFS and PPS based on individual patient data,
and log-normal distributions for SAE amounts, costs,
and PFS HRs. In case of unknown SE, 20% of mean
value was used.Outcomes
The primary outcome of the analysis was cost-
utility measured as the incremental cost-effectiveness
ratio (ICER), which is the ratio of the cost and quality-
adjusted life-year (QALY) difference between 2 inter-
ventions. The ICERs were determined versus the most
affordable and the most efﬁcient option. The efﬁcient
nondominant options were also depicted as the cost-
effectiveness efﬁciency frontier.44 Bayesian treatmentApril 2016ranking (BTR) was used to incorporate risk
assessment to the ranking of the lowest ICERs (best
relative value with euro), best quality-adjusted surviv-
als (highest QALY gains), and impact investing.
The secondary outcomes included incremental cost
per life-year gained, uncertainty assessment in terms of
the cost-effectiveness acceptability frontier (CEAF), and
expected value of perfect information per patient (EVPI).
The CEAF illustrates the optimal treatments with the
highest expected monetary net beneﬁt (pay-off) as a
function of willingness-to-pay (euro/QALY gained). The
EVPI demonstrates the maximum monetary value of
total parameter uncertainty that can be resolved by
acquiring perfect evidence for the included model param-
eters or alternatively the expected net monetary conse-
quences related to a “wrong” resource allocation
decision.45–47 In Finland, the interpretation of cost-
effectiveness is complicated because the decision-maker’s
willingness-to-pay is not publicly announced,48 and,
thus, the CEAF and EVPI complement the primary
outcomes. Based on our experience, the maximum
willingness-to-pay for CLL would be approximately
€50,000/QALY gained, and values less than €30,000/
QALY (€20,000/QALY) gained are likely to indicate
good (very good) cost-effectiveness, respectively. These
ﬁndings are in line with similar UK thresholds.27
Because ICER and CEAF are sensitive to the
number of comparators included (and EVPI may be
also), results excluding Clb were also reported.49 Clb
may not be a relevant ﬁrst-line treatment, and Clb
results were based on stage 1 in CLL11.
To increase the clinical appeal and interpretation of
CEA ﬁndings, the modeled primary and secondary
results were used to develop tertiary results to comple-
ment them. The tertiary analysis approach was a CBA
type (a form of clinical value analysis that could be
labeled as drug cost–beneﬁt approach), which essen-
tially analyzes results during PFS and can include less
extrapolation uncertainty in its limited perspective.
Main CBAs were performed in terms of cost per
QALY or PFS year gained during PFS (relative beneﬁt
assessment) and the length of beneﬁt obtained with a
ﬁxed limited drug or PFS budget (absolute beneﬁt
assessment, impact investment) of €20,000 per pa-
tient. The impact investment analysis (IIA) incorpo-
rates an explicit willingness-to-invest value (ie, here
assumed to be €20,000/patient) and thus illustrates
the mean outcome in terms of a single unit (ie, time in
years).895
Clinical TherapeuticsRESULTS
The ICERs (euro/QALY gained) compared with the
most affordable treatment (Clb) were as follows:
GClb, €29,334; RClb, €43,958; RB, €59,316; and
OClb, €82,159. At the willingness-to-pay threshold ofTable II. Probabilistic base-case results: incremental cost
years (QALYs), life-years gained (LYG), and p
2.5%–97.5% percentiles [2000 iterations]).
Primary Outcome
Cost-Utility Analysis:
ICER, €/QALY Gained
Treatment Versus Clb Versus RClb GClb V
GClb 29,334 20,038 –
RClb 43,958 RClb versus 20,0
RB 59,316 Dominated 11,5
OClb 82,159 639 15,5
Clb – 43,958 29,3
Total QALYs
Treatment Mean 95% CrI Mea
GClb 3.75 3.35–4.18 5.7
RClb 3.11 2.73–3.51 5.0
RB 3.10 2.60–3.68 5.0
OClb 2.93 2.48–3.38 4.8
Clb* 2.71 2.33–3.11 4.5
PF QALYs
Treatment Mean 95% CrI Mea
GClb 2.03 1.80–2.29 2.7
RClb 1.16 1.06–1.25 1.5
RB 1.16 0.74–1.74 1.5
OClb 0.92 0.67–1.22 1.2
Clb* 0.73 0.64–0.83 0.9
PP QALYs
Treatment Mean 95% CrI Mea
GClb 1.71 1.35–2.10 3.0
RClb 1.96 1.58–2.34 3.4
RB 1.94 1.55–2.36 3.4
OClb 2.01 1.62–2.41 3.5
Clb* 1.98 1.61–2.37 3.5
Clb ¼ chlorambucil alone; Dominated ¼ more costly and less
chlorambucil; OClb ¼ ofatumumab þ chlorambucil; PF ¼ pro
state. RB ¼ rituximab þ bendamustine; RClb ¼ rituximab þ ch
*Based on CLL11 stage 1, others based on CLL11 stage 2.
896€30,000/QALY gained threshold, only GClb was cost-
effective compared with Clb. The ICERs for the most
efﬁcient option (GClb) compared with other combination
treatments were below the most acceptable willingness-to-
pay threshold (€11,556–€20,038) (Table II).-effectiveness ratios (ICER) and quality-adjusted life
ayer costs with their 95% credibility intervals (CrI;
Cost-Effectiveness Analysis:
ICER, €/LYG
ersus Versus Clb Versus RClb GClb Versus
24,474 18,035 –
38 32,896 RClb versus 18,035
56 45,238 Dominated 10,210
86 53,278 580 14,051
34 – 32,896 24,474
LYGs Costs, €
n 95% CrI Mean 95% CrI
5 5.11–6.45 42,467 39,001–46,876
5 4.38–5.73 29,810 26,221–34,577
2 4.25–5.82 34,972 31,444–39,571
4 4.12–5.54 29,690 25,950–34,544
1 3.85–5.18 12,159 8657–17,066
LYGs Costs €
n 95% CrI Mean 95% CrI
1 2.42–3.02 34672 33,381–36,231
7 1.46–1.68 21031 20,207–22,014
7 1.02–2.33 26160 24,937–27,497
8 0.96–1.67 20604 19,512–22,016
9 0.87–1.12 3055 2591–3594
LYGs Costs (€)
n 95% CrI Mean 95% CrI
4 2.41–3.70 7796 4721–11,896
8 2.83–4.15 8779 5364–13,643
5 2.76–4.15 8812 5475–13,316
6 2.90–4.27 9086 5563–13,793
2 2.87–4.19 9104 5674–14,045
effective than its comparator; GClb ¼ obinutuzumab þ
gression-free health state; PP ¼ progressive disease health
lorambucil.
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Figure 3. Cost-effectiveness plane with expec-
ted (discounted) lifetime costs, qual-
ity-adjusted life-years, and cost-effec-
tiveness efficiency frontier (CEEF)
(incremental cost-effectiveness ratio
[ICER] ¼ euro/quality-adjusted life-
year gained). Clb ¼ chlorambucil
alone; GClb ¼ obinutuzumab þ
chlorambucil; OClb ¼ ofatumumab
þ chlorambucil; RB ¼ rituximab þ
bendamustine; RClb ¼ rituximab þ
chlorambucil.
E. Soini et al.According to the cost-effectiveness efﬁciency fron-
tier (Figure 3, Table II), RClb, RB, and OClb were
extendedly dominated by GClb and Clb. The ICERs
for OClb versus Clb, and RB versus Clb, were
€82,159 and €59,316, respectively, which may not
be cost-effective.
Based on the conditional BTR of smallest ICER
versus Clb (ie, the highest value for money), GClb was
the most cost-effective (ie, efﬁcient) treatment, with
92.9% probability; RB had 3.7% probability. The
second most cost-effective treatments were RClb and
RB, with probabilities of 72.8% and 21.7%, respec-
tively. The third most cost-effective treatments were
RB and OClb, with 65.2% and 34.8% probabilities.
Consequently, GClb was the ﬁrst best option, with
only 7.1% risk of wrong allocation, RClb was second
best option with 27.2% risk, and RB was third best
option with 34.8% risk.
Secondary Outcomes
The average discounted survival ranged from 4.51
(Clb) to 5.75 (GClb) years (Table II). The discounted
quality-adjusted survival ranged from 2.71 (Clb) toApril 20163.75 (GClb) QALYs (Supplemental Figure 1), whereas
the respective lifetime costs ranged from €12,159
to €42,467 (Supplemental Figure 2) (both as shown
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2016.02.005).
Based on the QALY and life-year differences, GClb
was considerably more effective compared with the
other treatments based on the 2.5% to 97.5% per-
centiles. Based on the BTR of greatest expected
quality-adjusted survival (QALYs gained), GClb was
the most effective, with 99.9% probability; RB had a
probability of 0.1%. The second most effective treat-
ments were RClb and RB, with 56.2% and 41.5%
probabilities, respectively. The third most effective
treatments were RB and OClb, with 81.1% and
18.9% probabilities. The fourth most effective rank
was OClb, with 98.7% probability. Consequently,
GClb is the ﬁrst most effective option with only a
0.1% risk of wrong inference; RClb is the second
most effective option, with a 43.8% risk; RB is third,
with an 18.9% risk; and OClb is the fourth most
effective option, with only 1.3% risk.
Costs for treatment acquisition (5%–64%), treat-
ment administration/monitoring (10%–14%), and
progression (18%–75%) were the biggest cost drivers
for total costs (Supplemental Figure 2 [as shown in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2016.02.005]).
The ICERs compared with stage 1 Clb were as
follows: GClb, €24,474/life-year gained; RClb,
€32,896/life-year gained; RB, €45,238/life-year
gained; and OClb, €53,278/life-year gained. The
ICER of GClb versus RClb was €18,035/life-year
gained, demonstrating the extended dominance of
GClb and Clb over other treatments.
Sensitivity Analyses for Primary and Secondary
Outcomes
Multinomial cost-effectiveness acceptability curves
were drawn (Supplemental Figure 3 [as shown in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2016.02.005). In summary, Clb and GClb constituted
the CEAF (Figure 4A). At €30,000 and €50,000/
QALY gained, GClb had 54% and 99% probability
for cost-effectiveness, respectively. The respective
mean EVPIs were €1438 (2.5%–97.5% percentile,
€0–€7379) and €44/patient, indicating low to
moderate value of additional research to support
decision-making or opportunity loss for a wrong897
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Figure 4. Cost-effectiveness acceptability fron-
tiers (CEAF) and expected value of
perfect information (EVPI) for com-
parison (A) including and (B) exclud-
ing Clb. Rituximab þ bendamustine
was never on CEAF (see also Supple-
mental Figure 3, as shown in the
online version at http://dx.doi.org/
10.1016/j.clinthera.2016.02.005). Clb ¼
chlorambucil alone; GClb ¼ obinutu-
zumab þ chlorambucil; OClb ¼
ofatumumab þ chlorambucil; RClb ¼
rituximabþchlorambucil.
Clinical Therapeuticsdecision. The maximum mean EVPI was €1739 per
patient (€0–€8182).
Combination Treatment Comparison
OClb, RClb, and GClb constituted the CEAF in the
comparison excluding Clb (Figure 4B). At €30,000
and €50,000/QALY gained, GClb had 90% and 99%
probability for cost-effectiveness, respectively. The
respective mean EVPIs were €204 (€0–€2797) and898€42/patient, indicating very low value of additional
research or loss for a wrong decision. The maximum
mean EVPI was €1562/patient (€0–€7827).
Scenario Analyses
The relative base-case results were robust for
various changes in method, population characteristic,
efﬁcacy, QoL, and cost inputs (Supplemental
Appendix I [as shown in the online version at http://
dx.doi.org/10.1016/j.clinthera.2016.02.005]).
Scenario analyses produced lower mean ICERs for
GClb (difference in ICER, –2340), RClb (–913), and
RB (–306), and a higher mean ICER for OClb (5466)
compared with the deterministic base-case scenario.
Tertiary Outcomes
The tertiary objective was to elaborate on the
primary and secondary outcomes by using CBA.
Generally, CBA cannot fully substitute the primary
outcomes of standard CEA, if CBA ignores all other
than drug costs, differences in quality of life, differ-
ences in AEs, differences other than selected survival
parameters (eg, overall survival or PFS depending on
the selected approach), and concordance between
costs and beneﬁts (ie., costs and survivals are gained
from different timelines). Consequently, compared
with conventional standard CEA, CBA may result in
a high level of ignorance.
Based on the CBA (Supplemental Appendix II [as
shown in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.02.005]), GClb had the
highest relative clinical value, only a low risk for a
high cost–beneﬁt ratio, best clinical value–cost-
effectiveness relation, had the best impact on
investment, and made the best value out of budget.
In general, the CBA results concurred with the key
outcomes, and the conclusions were similar.DISCUSSION
This study illustrated the cost-effectiveness of ﬁrst-line
CLL treatments when RFC is unsuitable. The ICERs
compared with Clb treatment (primary outcomes)
were between €29,334 and €82,159/QALY gained,
and GClb demonstrated the best value for money
option and OClb demonstrated the worst. When
ranked, GClb had the highest probabilities of lowest
ICER versus Clb (the ﬁrst best payoff) and highest
QALY gain (the ﬁrst best effectiveness). In addition,Volume 38 Number 4
E. Soini et al.the potential cost-effectiveness was projected to be
achievable with low to moderate willingness-to-pay
thresholds when selecting GClb (ie, best overall value
with reasonable willingness-to-pay thresholds). Fur-
thermore, the value of conducting additional research
to support decision-making or loss from making a
wrong decision was low to moderate, and relative
results were robust based on the 26 different scenario
analyses. Finally, the developed CBA demonstrated
the best relative clinical value, the lowest risk for high
cost–beneﬁt ratio, the best clinical value–cost-effec-
tiveness relation, and the most value gained with the
limited budget (highest impact on investment) for
GClb. Both drug and PFS costs seemed to follow the
clinical value of drug, but the trend decreased as a
function of costs, meaning that more efﬁcient drugs
also had a lower cost–beneﬁt ratio; this scenario was
also observed in the key outcomes. Generally, the
CBA results and key outcomes concurred, but addi-
tional CEAs with different cancer types are needed
to assess the validity of CBA due to its inherent
limitations.
CBA is a clinical value assessment method that can
increase the clinical interpretation and appeal of
results; however, it cannot fully substitute the primary
outcomes of standard cost-effectiveness analysis. CBA
may ignore differences in a number of cost categories
(eg, treatment administration, monitoring, AEs, end-
stage treatment). Depending on the beneﬁt side, it may
also ignore the impact of QoL, AEs, and various types
of survival parameters. If CBA is performed without
further consideration, costs and beneﬁts may be
assessed from different timelines, and discounting
can be ignored. Thus, CBA can easily result in invest-
ment biases and partial optimization of limited budg-
ets. CBA as such should probably not be used as the
primary method of analysis without acknowledging its
limitations and their potential consequences, and its
results should be interpreted with caution. In the
present study, the objective of using CBA was only
to elaborate and complement the primary and secon-
dary outcomes.
The CBA provided new insights in the present
study. All the primary, secondary, and tertiary ﬁnd-
ings were based on a decision-analytic modeling
approach capable of synthesizing all the known
evidence. With direct data elicitation methods or
analysis of publications alone (eg, without handling
of local age- and gender-speciﬁc mortality or withoutApril 2016assessing the mean survival rates), CBA, as with any
piggy-back assessment, may lack agreement between
the beneﬁts and costs and may not concur with solid
standard modeled CEA results. Mean (not median)
survival is the expected value of distribution; costs are
usually means,50 and with means, arithmetic
calculations are feasible. As was performed in the
present study, dose–response should be accounted for
in the CBA. Consequently, CBA can offer new
insights, although it is not a simple procedure;
comprehensive methods and data are needed to
conduct a valid CBA.
As observed before, treatment tolerability has an
important role when the treatment response is not age
related.51 Since the early 1990s, the ﬁrst and relapsed/
refractory line cost-effectiveness of CLL treatments
have been modeled,52–57 and rituximab and bend-
amustine alone or as combinations with other treat-
ments have been found to provide reasonable value
for money. In this analysis, the ICER for RB versus
Clb was €59,316/QALY gained, a result that was
potentially not cost-effective.
Generally, health economic modeling results in the
simpliﬁcation of a more complex reality. The key
sources of uncertainty in this study were model
structure, parameter values (imprecision of parame-
ters), and patient variability. We discuss these uncer-
tainties in detail. First, the cost-effectiveness model
had 3 key health states in which PFS was divided into
on-and-off treatment, whereas other important factors
such as Binet staging and treatment inconvenience
were taken into account. However, the transition
probabilities derived considered these health states as
unique because of a lack of data.
In a previous study,53 concerns were raised that a
3-state Markov model structure was too simplistic for
CLL, which also applies for any simple data-based
analysis. Alternative modeling approaches (eg, AUC
modeling, in which overall survival is estimated on the
basis of PFS by using PFS as a surrogate end point for
overall survival and including a response for PFS
health state) are available. However, long-term data
on PFS and overall survival relationship, sample sizes,
and potential interaction information between treat-
ment and response were too sparse for the AUC or
PFS responder status modeling. Most importantly, the
selected approach unlikely beneﬁts the most cost-
effective treatment (GClb) because the PFS Kaplan-
Meier curves of GClb patients in CLL11 lay899
Clinical Therapeuticsconsistently above the RClb and Clb curves regardless
of response class.
Second, a median PFS was reached in all 3 treat-
ment arms in the latest CLL11 data-cut. However,
there was still censoring and uncertainty about the
best-ﬁtting function and its tail for PFS, in particular
for the GClb arm. The Weibull distribution was
selected because it provided a good ﬁt, had reasonable
tail shape, resulted in conservative estimates, and
enabled comparability with many other earlier CEAs.
A limitation of the meta-analysis used for OClb and
RB PFS estimation was the small number of trials
found in the evidence network. To indirectly incorpo-
rate evidence via HR, the proportional hazards
assumption should hold. This was checked by using
standard techniques, which held reasonably in the
CLL11 data. The relative results of this analysis were
also agreeable with another recent meta-analysis.58
However, the absolute results of this analysis were
more conservative, potentially indicating that the
effects and clinical value were not overestimated in
the CEA or CBA. Furthermore, the scenarios with
upper or lower 95% CI HR thresholds for the OClb
and RB PFS conﬁrmed that the cost-effectiveness of
GClb is not volatile to indirect data.
CLL11 data were not sufﬁciently mature to model
PPS. Because it was unknown in CLL11 whether PPS
depends on ﬁrst-line treatment received, the same
modeling approach for PPS was applied to all treat-
ment arms. In the CLL5 trial, the effect of the ﬁrst-line
treatment was not statistically signiﬁcant for the
prediction of PPS. However, GClb patients will
probably survive beyond the modeled overall survival
in this CEA, given the recent overall survival data.16
This result could further improve the cost-effectiveness
of GClb.
CLL5 used the earlier progression deﬁnition,59
whereas CLL11 used the updated progression
deﬁnition.60 The latter may be more sensitive because
imaging techniques gained a higher weight, and cytopenia
was added. However, the progression assessment in the
CLL5 and CLL8 trials was rigorously conducted.
The QoL variables applied were not provided
directly by the patients but were sourced through the
utility elicitation study. Lack of accuracy risk in the
vignettes was reduced by a staged approach with
input from literature, patients, and health care pro-
fessionals and by using the EQ-5D-3L dimensions.
The interviewees were younger than the CLL11900patients, and thus all QoL values were anchored to
Finland to capture the impact of comorbidities, age,
and Finnish preferences. When the general Finnish
population values43 and previous cancer QoL
studies5–8,61,62 were reviewed, there was no obvious
discrepancy with the anchored QoL values.
None of the earlier CEAs included consideration of
Binet stages, although they do have an impact on the
treatment decisions.13 Follow-up resource use was
based on Finnish clinical practice, in line with recom-
mendations, and speciﬁed for different Binet stages.
These resource estimates were lower than recent study
results, including a Danish study12 and a German study
using Elixhauser comorbidity scores and generalized
estimating equations.11 However, sensitivity analysis
showed that these Finnish results could be generalized
to a wider landscape, namely UK QoL and German
resource use were used in sensitivity analysis scenarios
and results were robust. The generalizability may also
be good in countries with similar cost structures (most
probably Nordic and maybe other European Union
countries). The biggest cost drivers were drug or
progression related, and those 2 seemed to have a
tradeoff. If relative costs related to progression were
high, drug costs and QALYs gained were low, and
vice versa.
Third, Finnish experience and CLL11 individual
patient data were used to deﬁne cohort characteristics,
and patients were elderly when they entered PPS. The
trial populations of CLL11 and CLL5 resembled each
other, and their Binet staging was incorporated into the
analysis. However, individual patient data were not
available for OClb or RB. Age was adjusted in the
network meta-analysis, but a risk of residual confounding
due to the 17p deletion status and Binet stages remained.
Patients included in the COMPLEMENT 1 study32 were
similar to CLL11 patients, with minor differences (they
were younger and were more frequently at Binet stage A).
In addition, when cumulative chlorambucil doses were
compared, the dose in CLL11 was at the lower end (with
circa 400 to 440 mg) compared with Knauf et al14 (with
circa 560 mg) or CLL5 (with circa 490 mg).
Thus far, there has been no publication of studies
regarding the effects and cost-effectiveness of the changes
in the CLL guidelines or response/progression criteria,
optimal chlorambucil regimen, or sequential modeling of
CLL (eg, Soini et al46,47). Studies regarding the impor-
tance of deﬁning disease staging and clinical end
points63, CBA and CEA relations, unconfounded PPSVolume 38 Number 4
E. Soini et al.survival38,64 and societal willingness-to-pay65 are also
needed. From the conventional perspective of extra-
welfarism (ie, maximize health beneﬁts), and lacking
data for per-patient incremental cost-effectiveness, these
results indicate that GClb should be selected for the
modeled patients, and the risk of making wrong
decisions is minor in terms of efﬁciency and effectiveness.
However, if the budget is not sufﬁcient for all patients
who need GClb, then an explicit target for PFS (and PFS
QALYs) that is thought to be societally “enough PFS”
for these patients should be set in a political decision-
making process and the treatment mix optimized condi-
tional on process.CONCLUSIONS
With €30,000/QALY gained or higher thresholds, GClb
was clearly the most cost-effective CLL treatment when
RFC was unsuitable. In general, GClb provided the best
value for money option in terms of relative and absolute
outcomes. The low to moderate value of additional
research or loss from a wrong decision was assessed.ACKNOWLEDGMENTS
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A: Patient Characteristics in Clinical Trials
Table A1Supplemental Table A1. Baseline patient characteristics between relevant trials
Used Pre-progression
Post-
progression
Characteristic / Trial
CLL11 [15]
Stage 2*
CLL11 [15]
Stage 1 (Clb)
COMPLEMENT
1† [32]
CLL10‡
[33] CLL5 [38]
Patients included 663 118 447 564 193
Enrolment time 4/2010-7/2012 12/2008-5/2011 10/2008-6/
2011
7/1999-9/
2004
Age, mean years 72§ 71§ na na 71§
Age, median (range) years 74 (39-90) 72 (43-87) 69 (35-92) 62 (33-82) 70 (65-79)
Age Z65 years na na 69% na 100%
Age Z70 years na na 49% na 100%
Men na na 63% na 64%
No comorbidity na na 13% na 34%
Comorbidities Z1 na na 87% na 34%
Comorbidities Z2 na na 72% na 33%
Comorbidities Z3 82%║ na na na
Cardiac comorbidity 51% 53% 21% na na
Hypertension comorbidity 68% 75% na na na
Vascular comorbidity 32% 29% 55% na na
Respiratory comorbidity 37% 36% 25% na na
Eye, ear, throat or larynx comorbidity 41% 45% na na na
Upper gastrointestinal comorbidity 31% 33% na na na
Lower gastrointestinal comorbidity 19% 21% na na na
Gastrointestinal comorbidity na na 25% na na
Hepatic or biliary comorbidity 18% 18% na na na
Renal comorbidity 43% 38% na na na
Genitourinary comorbidity 34% 37% na na na
Musculoskeletal comorbidity 43% 38% 29% na na
Metabolic comorbidity na na 36% na na
Endocrine or metabolic comorbidity 52% 54% na na na
Neurologic comorbidity 22% 28% na na na
Psychiatric comorbidity 16% 9% na na na
Eastern Cooperative Oncology Group
(ECOG) performance status 0
na na 38% na 44%
ECOG performance status 1 na na 54% na 50%
ECOG performance status 2 na na 8% na 6%
ECOG performance status Z3 na na 0% na 0%
Binet A 22% 20% 33% 22% 15%
Binet B 42% 42% 36% 38% 47%
Binet C 36% 37% 31% 40% 38%
(continued)
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Used Pre-progression
Post-
progression
Characteristic / Trial
CLL11 [15]
Stage 2*
CLL11 [15]
Stage 1 (Clb)
COMPLEMENT
1† [32]
CLL10‡
[33] CLL5 [38]
Creatinine clearance (CC) mL/min,
median
63 62 na na na
CC o70mL/min 64%§ 61%§ 48% 0% 62%§
CC Z70mL/min 36%§ 39%§ 52% 100% 38%§
6q deletion na na 54% no 17p/11q
deletion
na na
12q deletion na na na 21%
13q deletion 49%§ 59%§ na na
11q deletion 17%§ 15%§ 15% no 17p
deletion
na 14%
17p deletion 7% 10% 6% 0% 6%
Trisomy 12 20%§ 19%§ cut-off 20% na na
Cumulative Ilness Rating Scale for
Geriatrics (CIRS-G), median
(range)
8 (0-22) 8 (0-18) 9 (4-21) 2 (0-6) na
CIRS lower category, r6 24%§ 22%§ na 100% na
CIRS higher category, 46 76%§ 78%§ na 0% na
Immunoglobulin heavy chain (IGHV
or IGVH) unmutated
61% 58% 56% 61% 63%
F unsuitable based on clinical facts 100%¶ 100%¶ na 0%¶ na
F unsuitable based on age na na 39% 0%¶ na
F unsuitable based on comorbidities na na 19% 0%¶ na
F unsuitable based on age and
comorbidities
na na 14% 0%¶ na
F unsuitable based on age,
comorbidities, patient preference
or medical decision
na na 100% 0%¶ na
Previous anticancer treatment
received
0%¶ 0%¶ 0%¶ 0%¶ 0%¶
*Obinutuzumabþchlorambucil and rituximabþchlorambucil.
†Ofatumumabþchlorambucil.
‡Rituximabþbendamustine.
§Estimated from individual patient data (IPD on ﬁle) results.
║Based on all patients included to the CLL11 trial.
¶Logical assumption based on the inclusion criteria or treatments received.
na ¼ not available.
F ¼ ﬂudarabine.
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E. Soini et al.B. Treatment Costs of Adverse Events
Table B1Supplemental Table B1. Additional resources and costs associated with treatment-related severe adverse
events (SAE) included to the cost-effectiveness model based on the Finnish practice
Adverse event Specialized care Tests & imaging Medications & infusions Total
Type, severity grade Res. (€) Res. (€) Res. (€) (€)
Anemia / hemolytic anemia, 3-4 Visit 309.04 Blood red cells 2
units
414.04 723.08
CNS / intracranial hemorrhage, 5 Stay 2635.53 2635.53
Dermatitis allergic / atopic, 3 Corticosteroid
cream
7.71 7.71
Diarrhea, 3 Call 27.46 Electrolytes,
kidney
function
4.12 31.58
Gout, 3 Visit 309.04 Allopurinol,
paracetamol 1g
13.55 322.59
Hepatic enzyme increased, 3-4 Call 27.46 AST, ALT,
ALP, PTT,
INR
10.03 37.50
Hyperuricaemia, 4 Stay 1653.48 Allonopurinol,
paracetamol 1g,
i.v. NaCl
1000 ml
121.55 1775.03
Infection, 3 Visit 309.04 309.04
IRC: Bronchospasm / dyspnea /
larynx spasm / stridor /
wheezing, 3-4
þ1h
time
24.50 Methylpredni-
solone
125 mg,
adrenalin
12.17 36.67
IRC: Chills / headache / pyrexia, 3 Paracetamol 1g 6.71 6.71
IRC: Hepatotoxicity, 4 Delay 309.04 309.04
IRC: Hypotension, 4 þ1h
time
24.50 i.v. NaCl
1000 ml
108.00 132.50
IRC: Nausea / vomiting, 3 Metoclopramide
10 mg
9.22 9.22
IRC: Tachycardia, 3 Bisoprolol 8.61 8.61
IRC: Thrombocytopenia, 3 Visit 309.04 Full blood
count
2.53 311.58
IRC: Urticaria, 3 Cetirizine 10 mg 9.55 9.55
Leukopenia, 3-4 Call 27.46 Full blood
count
2.53 30.00
Mucosal inﬂammation, 3 Visit 309.04 Amphotericin B 39.16 348.20
Neutropenia / granulocytopenia, 3 Visit 309.04 GCSF 318.06 627.10
Neutropenia / granulocytopenia, 4 Stay 1653.48 i.v. antibiotic,
GCSF
449.41 2102.89
(continued)
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Adverse event Specialized care Tests & imaging Medications & infusions Total
Neutropenic sepsis, 4 Stay 6556.25 i.v. antibiotic,
GCSF
449.41 7005.66
Pancytopenia, 3 Call 27.46 Full blood
count
2.53 30.00
Pancytopenia, 4 Stay 1653.48 GCSF,
trombocytes
4-8, blood red
cells 1-2
1843.13 3596.61
Platelet count decreased, 3 Call 27.46 Full blood
count
2.53 30.00
Pneumocystis jirovecii pneumonia, 3 Stay 2330.92 i.v. antibiotic,
corticosteroid
147.32 2478.24
Pneumonia, 3-4 Stay 2330.92 i.v. antibiotic 131.35 2462.27
Pneumonitis, 3 Visit 309.04 Thorax x-ray 35.91 344.95
Pyrexia, 3 Visit 309.04 Paracetamol 1g 6.71 315.17
Rash maculo-papular / pruritic, 3 Visit 309.04 Cetirizine
10 mg, steroid
cream
17.26 326.30
Renal impairment, 3 Call 27.46 Creatinine 2.53 30.00
Renal failure, 3 Visit 309.04 309.04
Renal failure, 4 Stay 3028.54 3028.54
Sepsis, 3-4 Stay 6556.25 i.v. antibiotic 131.35 6687.60
Thrombocytopenia, 3 Visit 309.04 Full blood
count
2.53 311.58
Thrombocytopenia, 4 Stay 1653.48 Platelet
transfusion 4-8
units
1211.03 2 864.51
Varicella, 3 2 visits 618.08 618.09
Res. ¼ resource. CNS ¼ central nervous system. IRC ¼ infusion-related complication. GCSF ¼ granulocyte-colony stimulating
factor. AST ¼ aspartate aminotransferase. ALT ¼ alanine aminotransferase. ALP ¼ alkaline phosphatase. PTT ¼ partial
thromboplastin time. INR ¼ international normalized ratio.
Clinical TherapeuticsC: Scenario-Type Sensitivity Analyses
The following sensitivity analyses were implemented
using the deterministic (mean value) modeling method.Methods9Deterministic: base case results using deterministic
modeling. Undiscounted: No discounting of results was done.
 10 year horizon: Time horizon was limited to 10
years in the modeling.04.e4 5 year horizon: Time horizon was limited to 5 years
in the modeling. 3.5 year horizon: Time horizon was limited to 3.5
years (within CLL11 trial setting, basically no
extrapolation) in the modeling.
Population CLL11 cohort: All modeled population character-
istics from CLL11 trial. Fit cohort: Modeled population characteristics
from CLL8 trial [64] (sc. ﬁt population: mean ageVolume 38 Number 4
E. Soini et al.60 years, Binet stages 5%, 64% and 31% for A, B
and C, respectively) and also PPS (exponential
distribution’s parameter values (standard errors):
intercept 5.427 (0.533) and age -0.021 (0.008) 31st
October 2011 data cut)) was applied to test the
sensitivity of the results to cohort characteristics
(“generalizability” to a wider population).
EfficacyAExponential PFS: PFS modeled based on exponen-
tial survival distribution. LogLogistic PFS: PFS modeled based on LogLogis-
tic survival distribution. LogNormal PFS: PFS modeled based on LogNor-
mal survival distribution. Gamma PFS: PFS modeled based on Gamma
survival distribution. Gompertz PFS: PFS modeled based on Gompertz
survival distribution. KM PFS: Kaplan-Meier estimates with a parametric
tail were used for the extrapolation. 95%CI HL PFS HR: PFS adjustment GClb vs.
using the indirect comparators set to the 95% CI
higher threshold of HR (OClb 0.43, RB 0.72). 95%CI LL PFS HR: PFS adjustment GClb vs. using
the indirect comparators set to the 95% CI lower
threshold of HR (OClb 0.19, RB 0.21). λ ¼ 0.80: 20% lower failure probability assumed
for PPS. λ ¼ 1.20: 20% higher failure probability assumed
for PPS.
Quality of Life No IV disutility: QoL on intravenous treatment
assumed to be the same as QoL on per os treatment.pril 2016 No visit disutility: No disutility due to increased
hospital visits assumed. Higher PPS QoL: PPS QoL assumed to be similar to
QoL on per oral treatment. Foreign QoL: QoL values were not anchored to
Finland.
Costs and Resource Use Label doses: Drugs were used according to
their label. Vial sharing & non-ﬁt RB dose: Drugs left in vials
can be shared and, for non-ﬁt, the bendamustine
dose may be 50-75mg/m2 (on average, 60mg/m2
was used for bendamustine).
 No additional administration visit: No additional
visit may be needed for the drug administration and
only nurse/bed time was taken into account (cycle
1/later cycles: GClb €392.00/79.63, OClb €257.25/
98.00, RB €245.00/85.75, RClb €196.00/36.75,
respectively). CLL11 AEs based on the publication [15].
 Hospital perspective: estimated patient co-
payments and costs for reimbursed treatments
(Clb) excluded. Foreign resources: Resource use not related to
drugs was based on a German study [11].
Results
Table C1.
D. Modeled Quality-Adjusted Survivals
Figure D1.
E. Cost Drivers by Treatment
Figure E1.904.e5
Supplemental Table C1. Sensitivity analyses results (deterministic analysis, 20 year time horizon, and 3%
discounting per annum if not otherwise stated) demonstrated the robustness of
relative base case results
Methods Determ-
inistic
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29497 44433 59176 81663
Costs (€) 42101 29595 34697 29401 11797 GClb
vs.
- 19953 11562 15644
Undisc-
ounted
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.171 3.448 3.434 3.245 3.001 vs. Clb 26191 40200 53242 72807
Costs (€) 43674 30994 36087 30747 13046 GClb
vs.
- 17539 10299 13956
10- year
horizon
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.474 2.901 2.888 2.725 2.525 vs. Clb 31574 46984 62781 87522
Costs (€) 40916 28648 33751 28493 10956 GClb
vs.
- 21436 12232 16597
5- year
horizon
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 2.655 2.288 2.274 2.146 1.996 vs. Clb 44091 59277 80523 115612
Costs (€) 37669 25932 31041 25926 8612 GClb
vs.
- 31996 17420 23059
3.5- year
horizon
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 2.113 1.885 1.870 1.769 1.655 vs. Clb 63072 74195 103295 151050
Costs (€) 36016 24193 29335 24276 7103 GClb
vs.
- 51839 27474 34057
Population CLL11
cohort
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29510 44435 59180 81659
Costs (€) 42035 29520 34624 29325 11721 GClb
vs.
- 19971 11577 15660
Fit cohort Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.046 3.434 3.417 3.249 3.022 vs. Clb 29530 43338 58013 77821
Costs (€) 43538 31131 36220 30947 13295 GClb
vs.
- 20253 11635 15792
Efficacy Expon-
ential
PFS
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.185 3.229 3.092 2.846 2.728 vs. Clb 20591 34292 60256 147874
Costs (€) 41779 28943 33674 29231 11771 GClb
vs.
- 13419 7410 9369
Log-
Logistic
PFS
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.112 3.183 3.141 2.944 2.777 vs. Clb 22491 43940 63158 105767
Costs (€) 41753 29573 34679 29398 11737 GClb
vs.
- 13116 7283 10582
Log-
Normal
PFS
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.361 3.201 3.172 2.935 2.763 vs. Clb 18625 40617 55861 102168
Costs (€) 41555 29598 34667 29415 11781 GClb
vs.
- 10308 5793 8514
Gamma
PFS
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.719 3.144 3.099 2.929 2.718 vs. Clb 30284 41837 60087 83287
Costs (€) 42110 29611 34698 29401 11805 GClb
vs.
- 21734 11961 16099
(continued)
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Gomp-
ertz
PFS
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.606 3.097 3.079 2.912 2.708 vs. Clb 33789 45762 61377 86553
Costs (€) 42154 29597 34570 29410 11805 GClb
vs.
- 24650 14383 18341
KM PFS Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 5.875 3.602 3.610 3.153 3.032 vs. Clb 10444 30675 39194 144680
Costs (€) 41757 29534 34711 29536 12066 GClb
vs.
- 5376 3110 4489
95%CI
LL
PFS
HR
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.456 3.114 2.714 vs. Clb 29497 44433 30628 43785
Costs (€) 42101 29595 34525 29305 11797 GClb
vs.
- 19953 26557 20393
95%CI
LL
PFS
HR
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 2.809 2.763 2.714 vs. Clb 29497 44433 241074 365305
Costs (€) 42101 29595 34503 29439 11797 GClb
vs.
- 19953 8143 12933
λ ¼ 0.8 Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.084 3.508 3.491 3.333 3.113 vs. Clb 30937 44951 60450 80032
Costs (€) 43620 31338 36424 31188 13563 GClb
vs.
- 21318 12126 16546
λ ¼ 1.2 Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.492 2.829 2.818 2.637 2.425 vs. Clb 28567 44087 58319 82929
Costs (€) 40994 28328 33442 28103 10514 GClb
vs.
- 19107 11208 15079
Quality of
life
No IVdis-
utility
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.754 3.131 3.117 2.949 2.714 vs. Clb 29152 42699 56862 75163
Costs (€) 42101 29595 34697 29401 11797 GClb
vs.
- 20084 11627 15770
No visit
dis-
utility
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.753 3.115 3.101 2.930 2.714 vs. Clb 29169 44433 59176 81663
Costs (€) 42101 29595 34697 29401 11797 GClb
vs.
- 19591 11356 15424
Higher
PPS
QoL
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 4.073 3.493 3.476 3.318 3.097 vs. Clb 31063 44957 60449 79971
Costs (€) 42101 29595 34697 29401 11797 GClb
vs.
- 21574 12407 16811
Foreign
QoL
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.955 3.292 3.278 3.097 2.869 vs. Clb 27915 42043 55995 77257
Costs (€) 42101 29595 34697 29401 11797 GClb
vs.
- 18884 10942 14806
Resource
use
Label
drug
doses
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29540 44481 62641 81653
Costs (€) 42147 29616 36040 29401 11799 GClb
vs.
- 19992 9536 15701
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Vial
sharing,
low RB
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29497 41302 57580 81663
Costs (€) 42101 28341 34080 29401 11797 GClb
vs.
- 21953 12526 15644
Hospital
pers-
pective
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29515 44246 60597 77729
Costs (€) 41086 28487 34214 27520 10763 GClb
vs.
- 20102 10732 16712
No add-
itional
visit
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 26757 39766 50557 71807
Costs (€) 39286 27725 31362 27276 11797 GClb
vs.
- 18444 12374 14794
CLL11
AEs
from
[15]
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 29343 44332 59637 82490
Costs (€) 41476 29376 34697 29401 11618 GClb
vs.
- 19764 11036 15230
Foreign
res-
ources
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.742 3.115 3.101 2.930 2.714 vs. Clb 31474 46006 60854 82983
Costs (€) 43452 29545 34666 29005 11116 GClb
vs.
- 22188 13720 17796
Average All sensit-
ivity
anal-
yses
Outcome GClb RClb RB OClb Clb ICER GClb RClb RB OClb
QALYs 3.809 3.109 3.090 2.905 2.704 vs. Clb 27238 43553 58882 86912
Costs (€) 41634 29155 34278 29006 11527 GClb
vs.
- 17812 10232 13966
QALY ¼ quality-adjusted life year. Clb ¼ chlorambucil alone. OClb ¼ ofatumumab þ chlorambucil. RClb ¼ rituximab þ
chlorambucil. RB ¼ rituximab þ bendamustine. GClb ¼ obinutuzumab þ chlorambucil. ICER ¼ cost (€) per QALY gained.
Clinical TherapeuticsF. Multinomial Cost-Effectiveness Acceptability
Curves
Figure F1.G. Clinical Value Analysis (CVA)
Cost-Beneﬁt Analysis (CBA, a type of CVA – also
called as Drug Cost-Beneﬁt Analysis, DCBA) was devel-
oped based on the decision analytical modelling results.
For some parts, CBA can be more clinically appealing and
easier to understand in practice than incremental cost-
utility analysis. However, CBA has few inherent limita-
tions which were shortly discussed in the main article.
The CBA with drug costs only included mean drug
costs based on the actual ﬁrst-line drugs consumed
(wastage assumed) and ignored other (e.g. adminis-
tration, monitoring, adverse event, end-stage) costs –
the perspective of analysis was limited to oncologic
drug payer perspective. PFS payer perspective results904.e8were reported as sensitivity analysis and included all
mean PFS time direct costs. The clinical outcomes of
CBA were also modelled as means.
Here, as examples, following tertiary outcomes
were reported in terms of CBA: Relative beneﬁt assessment based on PFS years
gained (includes the potential “trial value” of drug
during PFS) and PFS QALYs gained (includes the
potential “full value” of drug) Absolute beneﬁt assessment (investment impact assess-
ment, IIA) based on QALYs, and PFS and OS years
gained with limited assumed drug budget of €20,000/
patient.
Results
As was observed based on the Table G1 and
Figure G1, CBA results concurred well with the keyVolume 38 Number 4
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Figure D1. Discounted 10-year quality-adjusted survivals.
Detailed legend: QALY ¼ quality-adjusted life year. Clb ¼ chlorambucil alone. OClb ¼
ofatumumab þ chlorambucil. RClb ¼ rituximab þ chlorambucil. RB ¼ rituximab þ bendamus-
tine. GClb ¼ obinutuzumab þ chlorambucil.
E. Soini et al.cost-utility analysis results reported in the main article.
The results indicated the best relative clinical value and
most efﬁcient use of limited budget for GClb.
Due to assumption of no survival beneﬁts after
progression, lifetime CBA and key results concurred
less well with each other (Figure G2).GClb RClb Clb
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April 2016When these results (Table G1, Figure G1 and G2)
were interpreted, caution was needed: the comparator
for cost per beneﬁt in average (i.e. not incremental)
analysis was basically instant death [65]. Thus, the
incremental relative beneﬁt vs. Clb was plotted to the
Figures G1–3 to demonstrate what was lost if the mostProgression
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Figure F1. Multinomial cost-effectiveness accept-
ability curves (mCEAC) and cost-effec-
tiveness acceptability frontier (CEAF)
for comparison either including (higher
part) or excluding (lower part) chlor-
ambucil alone (Clb). In the comparison
including (excluding) Clb, GClb was
optimal and potentially cost-effective
treatment with over 50% probability
for cost-effectiveness with the threshold
exceeding 29,558 (20,803) per QALY
gained, respectively. Detailed legend:
QALY ¼ quality-adjusted life year.
OClb ¼ ofatumumab þ chlorambucil.
RB ¼ rituximab þ bendamustine.
RClb ¼ rituximab þ chlorambucil.
GClb ¼ obinutuzumab þ chlorambu-
cil. RB was newer on the CEAF.
Clinical Therapeuticseffective treatment was not selected and the cheapest
or less effective option was taken. In this case, GClb
was the most beneﬁcial treatment and the loss of not
choosing it was the biggest. In addition, the cost-
beneﬁt ratio of GClb during progression-free time was
the lowest, meaning that every euro with GClb
produced the biggest effect. GClb resulted to best
relative clinical value–cost-effectiveness relation.
In order to assess the joint uncertainty around the
results, relative beneﬁt – cost-effectiveness planes were904.e10shown below (Figure G3) based on the probabilistic
analysis.
Based on the Figure G3, RB and OClb had high
risk for higher costs per beneﬁt when the results in
comparison to Clb were poor or negative. GClb and
RClb seemed to have low risk for higher costs per
beneﬁt. In patient level analysis, this observation could
be used as a tool for indicating poorer cost per beneﬁt
ratio through the incremental beneﬁt and multivariate
methods.
Based on the probabilistic results of PFS costs and
relative incremental PFS years in comparison to Clb,
GClb resulted to the highest relative PFS in compar-
ison to Clb with 99.9% probability based on Bayesian
Treatment Ranking (BTR). RClb resulted to second
highest relative PFS with 51.7% probability. RB
resulted to third highest relative PFS with 78.6%
probability.
Based on the probabilistic results of PFS costs and
relative incremental PFS QALYs in comparison to
Clb, GClb resulted to the highest relative PFS QALYs
in comparison to Clb with 99.9% probability based
on the BTR. RClb resulted to second highest relative
PFS QALYs with 51.4% probability. RB resulted to
third highest relative PFS QALYs with 80.5%
probability.
Finally, PFS and QALY beneﬁts gained with ﬁxed
limited drug and PFS cost budget of €20,000 were
estimated (Table G1, Figure G4) in IIA. Based on
these, obinutuzumabþchlorambucil resulted to
longest beneﬁts and made the best value of limited
budgets. On the other hand, RB seemed to make the
worst use of budgets (i.e. RB had the highest cost per
beneﬁt gained and lowest times with the ﬁxed budget).
Based on the probabilistic results of PFS costs and
PFS years, GClb resulted to the highest health impact
on €20 000/patient investment (mean 1.561 PFS
years, 2.5-97.5% percentiles 1.391–1.747) with
66.5% probability based on the BTR. RClb was
second best (1.494 PFS years, 1.388–1.611) with
81.9% probability. OClb was third best (1.239 PFS
years, 0.938–1.592) with 57.7% probability. RB was
fourth best (1.196 PFS years, 0.806–1.745). The BTR
probabilities were similar for the PFS cost per
PFS years.
Based on the probabilistic results of PFS costs and
PFS QALYs, GClb resulted to the highest health
impact on €20 000/patient investment (mean 1.173
PFS QALYs, 2.5-97.5% percentiles 1.032–1.322)Volume 38 Number 4
Table G1. CVA base for the CBA (relevant with italics), all with 3%/year discounting.
Relative benefit vs Clb (clinical value) GClb RClb RB OClb
QALYs PFS 177.1 % 58.1 % 58.7 % 26.2 %
QALYs lifetime 37.8 % 14.8 % 14.3 % 7.9 %
PFS years 172.1 % 58.3 % 58.7 % 29.2 %
OS years 27.2 % 11.9 % 11.2 % 7.3 %
Drug cost (, oncological drug cost) per GClb RClb RB OClb
QALY PFS 13 322 13 948 17 083 16 819
QALY OS 7 216 5 178 6 393 5 301
PFS year 10 017 10 283 12 616 12 136
OS year 4 704 3 196 3 952 3 207
PFS costs (, payer costs) per GClb RClb RB OClb
QALY PFS 17 021 18 087 22 483 22 207
QALY OS 9 220 6 714 8 414 6 999
PFS year 12 799 13 334 16 605 16 024
OS year 6 010 4 144 5 201 4 235
Lifetime costs (, payer costs) per GClb RClb RB OClb
QALY 11 252 9 501 11 188 10 035
OS year 7 334 5 865 6 915 6 072
PFS years with 20,000 budget GClb RClb RB OClb
Drug costs 1.997 1.945 1.585 1.648
PFS costs 1.563 1.500 1.204 1.248
PFS QALYs with 20,000 burget GClb RClb RB OClb
Drug costs 1.501 1.434 1.171 1.189
PFS costs 1.175 1.106 0.890 0.901
Detailed legend: QALY ¼ quality-adjusted life year. PFS ¼ progression-free survival. OS ¼ overall survival. GClb ¼
obinutuzumab þ chlorambucil. RClb ¼ rituximab þ chlorambucil. RB ¼ rituximab þ bendamustine. OClb ¼ ofatumumab þ
chlorambucil.
E. Soini et al.with 74.5% probability based on the BTR. RClb was
second best (1.101 PFS QALYs, 1.008–1.198) with
81.7% probability. OClb was third best (0.893 PFS
QALYs, 0.659–1.169) with 54.0% probability. RB
was fourth best (0.882 PFS QALYs, 0.584–1.299).
The BTR probabilities were similar for the PFS cost
per PFS QALYs.
In conclusion, the CBA demonstrated highest pay-
off for obinutuzumabþchlorambucil, when assessingApril 2016only its drug costs or PFS costs. Generally, the both
cost types seemed to follow the clinical value (mean
PFS) of drug in this case, but the trend decreased as
the function of costs meaning that more efﬁcient drugs
such as GClb had also lower cost-beneﬁt ratio and
higher health impact based on the investment. This
may be a result of decreasing marginal beneﬁt (an
assumption in health economics) and price competi-
tion to be studied elsewhere.904.e11
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Figure G1. DCBA results based on PFS years or PFS QALYs and first-line oncological drug or PFS costs.
Detailed legend: PFS ¼ progression-free survival. QALY ¼ quality-adjusted life year. GClb ¼
obinutuzumab þ chlorambucil. RClb ¼ rituximab þ chlorambucil. RB ¼ rituximab þ
bendamustine. OClb ¼ ofatumumab þ chlorambucil.
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Figure G2. DCBA results based on OS years or QALYs and PFS or lifetime costs.
Detailed legend: PFS ¼ progression-free survival. QALY ¼ quality-adjusted life year. GClb ¼
obinutuzumab þ chlorambucil. RClb ¼ rituximab þ chlorambucil. RB ¼ rituximab þ
bendamustine. OClb ¼ ofatumumab þ chlorambucil.
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Figure G3. Planes for PFS costs and PFS years,
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narios.
Detailed legend: PFS ¼ progres-
sion-free survival. QALY ¼ quality-
adjusted life year. GClb ¼ obinutu-
zumab þ chlorambucil. RClb ¼
rituximab þ chlorambucil. RB ¼
rituximab þ bendamustine.
OClb ¼ ofatumumab þ chlorambucil.
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Figure G4. IIA: PFS and QALY benefits gained
with fixed limited oncological drug
or PFS cost budget of 20,000/pa-
tient.
Detailed legend: IIA = impact in-
vestment analysis. PFS ¼ progres-
sion-free survival. QALY ¼ quality-
adjusted life year. GClb ¼ obinutu-
zumab þ chlorambucil. RClb ¼
rituximab þ chlorambucil. RB ¼
rituximab þ bendamustine.
OClb ¼ ofatumumab þ chlorambucil.
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